Glaukos Phase 4 Data Show iDose TR Outperforms in Glaucoma-Cataract Combination Procedure

The Quick Take

• Glaukos reported positive Phase 4 results showing iDose TR delivered superior eye pressure reduction when combined with cataract surgery.
• The randomized controlled trial enrolled patients with open-angle glaucoma or ocular hypertension undergoing routine cataract procedures.
• Multi-source coverage of the Phase 4 data signals market significance, strengthening iDose TR's clinical differentiation argument.

Glaukos Corporation's positive Phase 4 results for iDose TR in combination with cataract surgery mark a significant clinical milestone in the minimally invasive glaucoma surgery segment. The study enrolled patients with open-angle glaucoma or ocular hypertension and demonstrated superior intraocular pressure reduction versus cataract surgery alone. Phase 4 confirmatory data carry particular commercial weight because they support label expansion and payer coverage arguments in a reimbursement environment that increasingly demands real-world procedural evidence. The iDose TR is a sustained-release travoprost implant targeting the key failure mode of patient adherence in glaucoma management.

A positive Phase 4 readout in a combination procedure expands the addressable cataract surgery pathway for iDose TR, opening a high-volume, high-frequency surgical setting beyond standalone minimally invasive glaucoma surgery procedures. Peer ophthalmic device makers including Alcon, Johnson and Johnson Vision, and Bausch and Lomb face competitive differentiation pressure as iDose TR data strengthen the case for integrated pressure management during routine cataract operations. Ophthalmology practices and ambulatory surgery centers stand to benefit from bundled reimbursement structures, while glaucoma pharmaceutical companies targeting adherence management face incremental erosion from a device that removes the daily drop regimen.

The critical next catalysts are a potential FDA label expansion for the iDose TR combined-procedure indication and commercial payer coverage decisions in major US health systems. Investors should monitor GKOS management's guidance update at the next earnings call for iDose TR adoption rates and average selling price trends in the combination setting versus standalone procedures. The macro variable that determines whether this thesis holds is whether CMS includes combination glaucoma-cataract procedures in its reimbursement framework at favorable rates — a positive ruling accelerates ambulatory surgery center adoption, while an unfavorable ruling caps the addressable market.

Synthesized from 3 sources.